Ritlecitinib Efficacy in Adolescents With Alopecia Areata: A Real-World Experience

    February 2026 in “ International Journal of Dermatology ”
    P. Franzese, Anna Balato, Eugenia Veronica Di Brizzi … Elisabetta Fulgione
    Studysummary In a single-center study, adolescents with moderate-to-severe alopecia areata treated with ritlecitinib 50 mg daily for 24 weeks showed significant hair regrowth, with 27.3% achieving near-complete regrowth and 45.5% substantial improvement, without serious safety concerns, according to these researchers.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Dupilumab Induces Hair Regrowth in Pediatric Alopecia Areata: A Real-World, Single-Center Observational Study Archives of Dermatological Research · 2024
    2. Efficacy and Safety of Ritlecitinib in Adolescents with Alopecia Areata: Results from the ALLEGRO Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Trial Pediatric Dermatology · 2023
    3. Treatment of Moderate-to-Severe Alopecia Areata in Adolescents With Baricitinib: A Retrospective Review of 29 Patients Journal of The American Academy of Dermatology · 2023